Valuation : Rallybio Corporation

Market Cap 89.61M 77.21M 73.11M 66.27M 124M 8.56B 125M 868M 334M 4.36B 337M 329M 13.76B P/E 2026 *
-4.59x
P/E 2027 * -4.69x
Enterprise Value 89.61M 77.21M 73.11M 66.27M 124M 8.56B 125M 868M 334M 4.36B 337M 329M 13.76B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
68.67%
Yield 2026 *
-
Yield 2027 * -
1 day+0.75%
1 week-0.30%
Current month+0.51%
1 month-0.50%
3 months+6.00%
6 months+77.63%
Current year+207.44%
1 week 16.5
Extreme 16.5
17.06
1 month 16.5
Extreme 16.5
17.29
Current year 3.67
Extreme 3.6701
17.57
1 year 3.67
Extreme 3.6701
17.57
3 years 1.76
Extreme 1.7608
41.2
5 years 1.76
Extreme 1.7608
168
10 years 1.76
Extreme 1.7608
206.24
Manager TitleAgeSince
Chief Executive Officer 68 2023-07-31
Director of Finance/CFO 56 2023-01-31
Chief Tech/Sci/R&D Officer - 2023-01-31
Director TitleAgeSince
Chairman 69 2017-12-31
Director/Board Member 68 2023-07-31
Director/Board Member 60 2020-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/6/26 Exercice

Director

7,124 0.1344%
5/19/26
Adar1 Capital Management LLC
BuyCompany 10,200 0.1928%
5/15/26
Adar1 Capital Management LLC
BuyCompany 300 0.0057%
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%-0.30%+251.09%-62.06% 89.61M
-0.71%-6.35%-2.99%+9.37% 45.48B
+0.21%-2.98%+337.74%+520.30% 43.68B
+1.74%-2.24%+39.82%+20.85% 43.09B
+1.38%-3.28%+6.84%+73.19% 39.4B
-1.44%-5.26%+8.97%+39.76% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+19.75%+108.58% 16.4B
-0.31%-2.78%+10.78%+30.20% 14.24B
+1.93%-3.55%+82.00%+36.66% 13.28B
Average +0.52%-3.25%+83.78%+86.32% 26.49B
Weighted average by Cap. +0.41%-3.67%+74.63%+124.79%

Financials

2026 *2027 *
Net sales - -
Net income -25.6M -22.06M -20.88M -18.93M -35.51M -2.45B -35.69M -248M -95.39M -1.24B -96.14M -94.03M -3.93B -26.5M -22.83M -21.62M -19.6M -36.76M -2.53B -36.95M -257M -98.74M -1.29B -99.52M -97.34M -4.07B
Net Debt - -
Logo Rallybio Corporation
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Employees
7
Date Price Change Volume
26-09-11 US$16.88 +0.75% 6,627
26-09-10 US$16.75 -1.30% 6,142
26-09-09 US$16.97 +2.17% 9,033
26-09-08 US$16.61 -1.86% 7,026

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RLYB Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!